

# Food & Function

Accepted Manuscript



This article can be cited before page numbers have been issued, to do this please use: S. Ugidos-Rodríguez, M. C. Matallana-González and M. Sánchez-Mata, *Food Funct.*, 2018, DOI: 10.1039/C8FO00555A.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [author guidelines](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the ethical guidelines, outlined in our [author and reviewer resource centre](#), still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

1

2 **Lactose malabsorption and intolerance: a review**

3

4

5 Ugidos-Rodríguez, Santiago; Matallana-González, María Cruz; Sánchez-Mata,

6 María Cortes\*

7

8 Dpto. Nutrición y Bromatología II, Bromatología, Facultad de Farmacia.

9 Universidad Complutense de Madrid, Spain

10

11 \* corresponding author

12 Dpto. Nutrición y Bromatología II. Bromatología. Facultad de Farmacia.

13 Universidad Complutense de Madrid.

14 Pza. Ramón y Cajal s/n. 28040 Madrid, Spain

15 Phone: +34 91 394 1799; Fax +34 91 3941798

16 Email: cortesm@ucm.es

17 Word count including Abstract and References: 10319

18

19 Short title: Lactose intolerance: a review

20

## 21 **Abstract**

22 Food lactose and lactose intolerance is today a hot topic in food and nutrition  
23 knowledge. About 70% of the adult world population is lactose-intolerant, due to  
24 low levels of intestinal lactase, also called lactase-phlorizin hydrolase (LPH), a  
25  $\beta$ -D-galactosidase found in the apical surface of the intestinal microvilli. This  
26 may be due to the loss of intestinal lactase in adulthood, a condition transmitted  
27 by an autosomal recessive gene, which differs in humans according to race.  
28 According to the cultural-historical hypothesis, the mutation that allows the  
29 metabolization of lactose appeared about 10,000 years ago in the inhabitants of  
30 northern Europe where mammalian milk continued in the diet after weaning,  
31 and lactase-persistent populations were genetically selected in some areas.  
32 Many intolerant individuals can tolerate low levels of lactose in their daily diet.  
33 Probiotics have also been proposed as an alternative that could avoid some  
34 symptoms of lactose intolerance. Many products are marketed nowadays as  
35 alternatives to dairy products for lactose-intolerant individuals. However, rules  
36 for low-lactose foods are currently not harmonised in the European Union.  
37 As scientific knowledge on lactose intolerance has notably advanced in recent  
38 decades, the aim of this work was to review the current state of the knowledge  
39 on lactose and lactose intolerance, its diagnosis and clinical management, and  
40 the various food products that are offered specifically for non-tolerant  
41 individuals.

42 **Key words:** milk, lactose, lactose malabsorption, lactose intolerance, lactase  
43 enzyme, delactosation

## 44 1. INTRODUCTION

45 Milk and dairy products are widely consumed. According to the WHO/FAO,  
46 more than six billion people consume milk and its dairy product derivatives,  
47 most of these in developed countries. Total consumption has doubled since the  
48 1960s.

49 These products are in high demand due to their high nutritional value. They  
50 contain milk protein with a high biological value, including casein and  
51 lactalbumin, and also present varying amounts of fats, most of them constituted  
52 of saturated fatty acids. Milk is rich in vitamin A, D and riboflavin, but poor in  
53 iron and niacin, and is a source of calcium. The main carbohydrate in milk is  
54 lactose, which is not present in other kinds of foods.<sup>1</sup>

55 It is estimated that lactose represents 6% of the carbohydrates consumed in  
56 Western diets. Lactose can serve as a source of energy, but also facilitates the  
57 absorption of calcium, phosphate, manganese and magnesium; it is fermented  
58 by the gut microbiota and contributes to the development of gram-positive  
59 intestinal bacteria (such as *Bifidobacterium* species), thereby preventing the  
60 development of pathogenic microorganisms in the host.<sup>2</sup> Before absorption,  
61 disaccharides must first be hydrolyzed in the human digestive tract by the  
62 substrate-specific membrane enzymes present in the intestine. The enzyme  
63 lactase is responsible for the splitting of lactose into its two components,  
64 glucose and galactose.<sup>4</sup>

65 Lactose intolerance was described by Hippocrates (5<sup>th</sup> century BC) and Galenus  
66 (2<sup>nd</sup> century AD). Since then, milk is known to be able to produce diarrhoea and  
67 other gastrointestinal manifestations in certain people. However it was not until  
68 after the Second World War, with the delivery of humanitarian aid (including

69 milk) to countries in Africa and Asia, that it was noted that many people suffered  
70 from flatulence, nausea and diarrhoea shortly after the intake of milk. This was  
71 initially attributed to food infections, until researchers at Johns Hopkins Medical  
72 School discovered the key to lactose intolerance in 1965.<sup>5</sup> Nowadays it is widely  
73 known that some people are lactose-intolerant due to low levels of the enzyme.  
74 They reduce or eliminate the consumption of milk and dairy products because  
75 they present symptoms when they ingest this type of food, which may lead to  
76 less calcium intake in the diet.

77 The food industry has recently developed a wide range of products for people  
78 with this type of intolerance. Lactose-free milk and low-lactose dairy products  
79 produced by different methods are available on the market today.

80 However, the fact that some individuals can digest lactose and others not has  
81 lead to widespread misunderstanding in society. Numerous ideas have been  
82 raised in various forums, to the point of erroneously considering lactose as a  
83 harmful compound in the human diet.

84 As scientific knowledge of lactose intolerance has notably advanced in recent  
85 decades, the aim of this work is to review the present state of knowledge of  
86 lactose and lactose intolerance, the clinical management of this situation, and  
87 the various products used as food alternatives for non-tolerant individuals.

88

## 89 **2. - PROPERTIES AND METABOLISM OF LACTOSE**

### 90 **2.1. - Chemistry and biochemistry of lactose**

91 Lactose is a disaccharide composed of D-galactosyl  $\beta$  (1 $\rightarrow$ 4) D-glucose. It is  
92 slightly soluble in water (170 g/L at 15 $^{\circ}$  C),<sup>5</sup> exclusively present in the milk of  
93 mammals, and six times less sweet than sucrose.<sup>6</sup>

94 Lactose is obtained from milk serum by ultrafiltration, evaporation and  
95 subsequent crystallization, and was first isolated in 1633 by the Italian Fabrizio  
96 Bartoletti.<sup>7</sup>

97 Lactose in milk has two isomers:  $\alpha$ -lactose and  $\beta$ -lactose (the C<sub>4</sub> hydroxyl group  
98 of galactose in  $\alpha$  and  $\beta$  position respectively), which differ in their properties of  
99 solubility, crystallization, melting temperature and optical rotation. The  $\alpha$ -isomer  
100 has a solubility of 70 g/L at 15° C, a melting temperature of 202° C and -89.4°  
101 revolving power; while the  $\beta$ -isomer presents values of 500 g/L, 242° and -35° C  
102 respectively. The technological treatment of the foods affects the balance of  
103 both isomers in milk, depending mainly on the temperatures applied.

104 Lactose can also be found as anhydrous or hydrated. Hydrated  $\alpha$ -lactose is  
105 obtained by oversaturated crystallization at a temperature lower than 93.5° C; at  
106 higher temperatures, anhydrous  $\beta$ -lactose is obtained.<sup>5</sup>

107 Lactose is sensitive to heat, which can cause browning of the milk by the  
108 lactose joining to amino groups of milk proteins (Maillard reaction), and the  
109 caramelization of the lactose molecules.<sup>8</sup> Heat treatments can also cause the  
110 isomerization of lactose and produce small amounts of lactulose (galactosyl-  
111 fructose). Up to 0.8 g/L of this isomer can be found in sterilized milk.<sup>5</sup>

112 Lactose is synthesized in the mammary gland from glucose and galactose by  
113 the action of the enzyme lactose-synthetase; in the case of ruminants it is also  
114 synthesized from volatile acids such as propionic acid, which is produced in the  
115 rumen. Lactose synthetase has a subunit with galactosyltransferase activity,  
116 and another with regulatory actions ( $\alpha$ -lactalbumin). The former catalyzes the  
117 transfer of a galactosyl group from UDP-galactose towards the N-  
118 acetylglucosamine to form N-acetyllactosamine. Alpha-lactalbumin, in

119 combination with the first subunit, catalyzes the union of UDP-galactose and  
120 glucose to form the disaccharide. The concentration of the enzyme in the  
121 intestine of the foetus increases during the gestation period.<sup>9</sup>

122 Lactose is the main component of the dry matter in mammals' milk and its  
123 content is inversely proportional to fat and proteins. Its average value in human  
124 milk is 70 g/L, while cow milk has around 46 g/L, similar to milk from other  
125 mammals such as sheep and goats, which have 48 g/L and 41 g/L  
126 respectively.<sup>10</sup>

127 Due to its physical-chemical properties such as texture and adhesive qualities,  
128 in addition to its hydration properties and flavour, lactose is used as an  
129 ingredient in many foods such as processed meats, margarines, breakfast  
130 cereals and ready meals, as well as food supplements and as an excipient in  
131 medicaments. For use as an ingredient, anhydrous lactose must meet some  
132 requirements of purity and identity: richness of no less than 99% m/m, just one  
133 molecule of water of crystallization, and humidity no higher than 6%.<sup>11</sup>

134

## 135 **2.2. - Lactose metabolism**

136 For its physiological use in the human body, lactose must be previously  
137 hydrolyzed in the intestine by the lactase enzyme. Once the lactose reaches the  
138 proximal intestine, it is broken down into glucose and galactose. Both  
139 monosaccharides are absorbed by active transport mediated by membrane  
140 proteins: the transporter SGLUT 1 (Sodium-Glucose Linked Transporter 1),  
141 which co-transport glucose or galactose accompanied by two ions of Na<sup>+</sup> from  
142 the intestinal lumen towards the interior of the enterocyte. The  
143 monosaccharides subsequently spread to the blood either passively or by the

144 facilitating protein GLUT 2 (Glucose Transporter 2). Glucose is used as an  
145 energy source, while galactose may be transformed into glucose for its  
146 energetic use by the galactokinase and galactose-1Pi-uridylyltransferase, or be  
147 used as a component of glycolipids and glycoproteins.<sup>12,13</sup>

148 It is essential to underline the importance of lactose as a precursory molecule of  
149 fundamental metabolites in various processes in the human being after its  
150 enzymatic metabolism, such as the galactocerebrosides that form part of the  
151 plasma membranes of nerve cells, especially in the myelin sheath.<sup>14</sup>

152 Non-absorbed lactose has osmotic activity and attracts fluid and electrolytes  
153 into the intestinal lumen. It is fermented and hydrolyzed by intestinal bacteria  
154 producing gases such as H<sub>2</sub> and CO<sub>2</sub>. CH<sub>4</sub> can also be obtained after the  
155 reutilization of both gases by methanogenic flora. Breathing eliminates these  
156 gases after passing into the bloodstream. A certain amount of these gases will  
157 lead to flatulence. Short-chain organic acids such as butyric, acetic, propionic,  
158 succinic, formic and lactic acid are produced and decrease colonic pH. These  
159 products can be refermented by the bacterial flora or absorbed by the large  
160 intestine, as acetic, propionic and butyric acids that are absorbed in the caecum  
161 and the ascending colon to be used by different tissues.<sup>15</sup>

### 162 **2.2.1. - The lactase enzyme**

163 Lactase (EC 3.2.1.108; 3.2.1.62), also called lactase-phlorizin hydrolase (LPH),  
164 is a β-D-galactosidase found in the apical surface of the intestinal microvilli in  
165 the jejunum, and its occurrence gradually decreases towards the ileum. It is the  
166 least abundant intestinal disaccharide and does not have a substrate inductor  
167 effect through an increase in the ingestion of lactose as it happens to maltase  
168 and sucrase.<sup>16</sup> The lactase enzyme is produced as a precursory peptide of 220

169 KDa, which undergoes a considerable post-translational modification after its  
170 initial synthesis during its transport to the cell surface to become a mature yet  
171 still inactive protein of 150 KDa. The enzyme is activated due to the action of  
172 pancreatic trypsin which produces the excision of two amino acids.<sup>17</sup>

173 The enzyme has two active sites: the first hydrolyzes lactose, and the other  
174 hydrolyzes phlorizin (an aryl alpha-glucoside) as well as a range of dietary  
175 glycolipids. Its activity increases progressively in the human foetus, especially  
176 from the third trimester of gestation. It reaches its maximum at birth and then  
177 begins to decrease from the earliest months of life, and particularly between 3-5  
178 years, by up to 10%, then remains this way in many individuals for the rest of  
179 their lives.<sup>18</sup>

180 This occurs through a decrease in its synthesis and is due to lower gene  
181 expression, rather than to low consumption of dairy products as was previously  
182 thought.<sup>16</sup> Although this is the normal condition in most mammals; some human  
183 beings have kept the lactase activity, and thus the ability to use hydrolyze  
184 lactose and absorb their components during their whole life, leading to a group  
185 of lactase persistent (lactose tolerant individuals), which may be more or less  
186 abundant depending on ethnic groups. The exact mechanism involved in the  
187 decline of lactase activity at the end of breastfeeding is still unclear; however,  
188 part of the enzymatic activity persists after weaning, since the phlorizin site is  
189 used, in addition to by glycoside, by a large number of glycolipids in the diet.<sup>12</sup>

190 Due to the location of the enzyme on the edge of the intestinal villi, its activity is  
191 easily affected by aggression and lesions in the intestinal mucosa, and it is  
192 more vulnerable to potential damage than other disaccharides.<sup>19</sup>

193 The optimal activity of lactase occurs in the small intestine at pH 6-8; in the  
194 colon, acid lactic bacteria can hydrolyze lactose into glucose and galactose  
195 thanks to bacterial lactase; however in this part of the gut, the pH is 4, so  
196 bacterial lactase activity is diminished and less lactose fermentation occurs.

197 Bacterial hyperproliferation in the intestine can decrease the amount of lactase,  
198 as the bacterial elastases break down the brush border enzyme site. As a  
199 result, more lactose passes into the large intestine and is fermented by bacteria  
200 in the colon.<sup>16</sup>

201

#### 202 **2.2.1.1. - Genetics of lactase**

203 The gene that encodes lactase is located on the long arm of chromosome 2 in  
204 position 21 (2q21), and contains 17 exons.

205 Two possible polymorphisms (single nucleoid polymorphism, SNP), were  
206 sequenced by Enhattah *et al* in 2002, associated to the persistence or lack of  
207 lactase in adulthood (Table 1). These polymorphisms were found in a gene  
208 called MCM6 (minichromosome maintenance complex component 6) near the  
209 lactase gene. This gene is not directly involved in lactase synthesis, but  
210 overlaps a region of the lactase gene as a key that activates or inhibits the  
211 enzyme.<sup>20</sup>

212 The polymorphism C/T-13910 is the most frequent and is located at  
213 approximately 14Kb. It is based on the presence of one cytosine (C) or one  
214 thymine (T) in position 13910. The variant C/C is associated with the non-  
215 persistence of lactase (intolerant phenotype), while the variants C/T or T/T are  
216 related to the persistence of the enzyme's activity.<sup>21</sup>

217 The second polymorphism (G/A-22108) is located at 22kb; the presence of G/G  
218 (guanine/guanine) is associated to non-persistence, while variants G/A  
219 (guanine/adenine) and A/A (adenine/adenine) may cause lactase-persistent  
220 individuals.<sup>22</sup>

221 The enzyme is synthesized if at least one of the two variants of the gene  
222 associated with the persistence of lactose is present. Only when both  
223 expressions are altered is the enzyme's activity and the absorption of lactose  
224 reduced. Although these polymorphisms can be used as indicators of the  
225 persistence of lactase in the European population, they cannot be applied  
226 globally, since other polymorphisms have been identified in the same  
227 chromosomal region in the African population.<sup>23</sup> The polymorphisms found in  
228 African and Middle Eastern populations are C/G-13915 and G/C-14010, while  
229 T/G-14009 is found in Ethiopia.<sup>24</sup>

230 There are currently eleven gene polymorphisms that are grouped into four  
231 haplotypes called A, B, C and U. The first haplotype has a frequency of 86% in  
232 the population of northern Europe and only 36% in the south.<sup>16</sup>

233 The mechanisms responsible for the intolerant phenotype include: decline in  
234 mRNA production; or alteration in genetic transcription or translation and even a  
235 decline in the number of enterocytes that produce lactase.

236 The loss of intestinal lactase is transmitted by an autosomal recessive gene  
237 while the persistence of enzyme levels (similar to those found in infants) is  
238 inherited by an autosomal dominant gene.<sup>25</sup>

239 Other factors in addition to SNPs may contribute to a decline in mRNA but it is  
240 unclear what molecular mechanisms might account for changes in lactase  
241 expression. Epigenetic modifications in DNA and histone proteins could

242 contribute to lactase non-persistence as they effectively regulate gene  
243 transcription, differ markedly across tissues and cell types and also change in  
244 the same individual over time.<sup>26</sup>

245 With no symptoms, only 50% of enzymatic activity is necessary for a proper  
246 metabolization of lactose.<sup>27</sup> Diets with high starch content have been found to  
247 increase levels of mRNA and the amount of lactase, while a high content of  
248 long-chain triglycerides in the diet decreases the expression of the gene.  
249 Fructose, glucose, galactose and glycerol may also increase the activity of this  
250 enzyme.<sup>28</sup>

251

### 252 **3. – MANIFESTATIONS AND MAGEMENT OF LACTOSE MALABSORPTION** 253 **AND INTOLERANCE**

254 According to the definition proposed by the European Academy of Allergology  
255 and Clinical Immunology Subcommittee on Adverse Reactions to Food in 1995,  
256 food intolerances are those in which there is no immune intervention.<sup>29</sup> Lactose  
257 intolerance is an example of an intolerance caused by genome-diet interaction.

258 Lactose malabsorption occurs when a substantial amount of lactase is not  
259 absorbed in the intestine<sup>30-31</sup>. Two types of conditions can be established  
260 according to the degree of lactase activity: alactasia (total absence of lactase  
261 activity) and hypolactasia (very low lactase activity in the jejunal mucosa, with  
262 an imbalance between the amount of lactose ingested and the ability to  
263 hydrolyze). Lactose intolerance depends not only on the expression of lactase  
264 but also the dose of lactose, intestinal flora, gastrointestinal motility, small  
265 intestinal bacterial overgrowth and sensitivity of the gastrointestinal tract to the  
266 generation of gas and other fermentations products of lactose digestion.<sup>32</sup>

267 Lactose intolerance can also be categorized into four types, depending on its  
268 origin:

269 Congenital lactase deficiency

270 This type of lactose intolerance is a metabolic error in an autosomal recessive  
271 trait and is characterized by a total absence or a significant reduction in the  
272 enzyme, with a normal histology in the small intestine. It begins at birth and  
273 persists throughout the individual's life. It is rare, with very few cases in the  
274 world –most of them in Finland– and there is little knowledge of its molecular  
275 basis. The first exposure to breast milk or other types of products containing  
276 lactose produces a watery diarrhoea. In the past the consequences were fatal,  
277 although nowadays with early diagnosis and the provision of an adequate  
278 lactose-free diet, the death of the newborn can be prevented.<sup>33</sup>

279 Developmental lactase deficiency

280 This is due to low levels of lactase as a result of premature birth (28-32 weeks),  
281 since the enzyme's activity in the foetus increases from week 34 and reaches  
282 its maximum at birth. However, infants can endure this deficiency thanks to  
283 colonic bacterial metabolism: as colonic pH is reduced, colonization by other  
284 microbial species as *Bifidobacterium* or *Lactobacillus* is favoured, thus  
285 preventing diarrhoea and malnutrition.<sup>34</sup>

286 Primary lactase deficiency or adult hypolactasia

287 This is the most frequent form and is the result of the progressive and  
288 permanent decrease in enzymatic activity. This is rarely complete, and the level  
289 of lactase that persists is an important factor in the development of symptoms.  
290 The process and the time it occurs are variable; the most common average age  
291 is between 5 and 7 years and the maximum impact occurs between 30 and 40

292 years. In populations with a high prevalence of hypolactasia, the disorder  
293 normally appears around two years of age. In other populations with a lower  
294 prevalence, the first symptoms may appear between 11 and 14 years. In  
295 Caucasian individuals (prevalence of 25%), lactase activity usually continues  
296 until at least age 20.<sup>35</sup>

297 Approximately 70% of the world population presents this type of intolerance  
298 although there is great geographical variability, with large differences between  
299 geographic areas, ethnic groups and even subpopulations (Table 2). It is  
300 estimated that over 90% of the Asian population is lactose intolerant, and 60-  
301 70% of African Americans. In Europeans, or populations with European  
302 ancestors, the prevalence drops significantly, reaching 5% in countries such as  
303 Switzerland and Denmark. For example, in Spain the global percentages are  
304 similar to the rest of Europe, although some authors report a 13-15% variation  
305 in Barcelona (northeast) and 32.5% in Galicia (northwest). Approximately 50%  
306 correspond to elderly people.<sup>33,36,37</sup>

307 Several hypotheses have been suggested to explain this geographical diversity  
308 in the response, including the role of lactose in calcium absorption in countries  
309 located at high latitudes. According to the cultural-historical hypothesis, the  
310 mutation that allows the metabolization of lactose appeared about 10,000 years  
311 ago in the inhabitants of Northern Europe, according to DNA evidence from  
312 individuals at that time. This coincides with the start of the Neolithic period in  
313 that part of the continent and the beginning of livestock breeding and dairy  
314 production by North Europeans, and is related to the strong dependence on  
315 milk consumption in their diet which would increase the availability of calories  
316 and nutrients such as calcium and vitamin D (necessary for calcium

317 assimilation). The high prevalence of this mutation in this population is the result  
318 of selection, acting in favour of those who could consume milk, since they  
319 presented lower rates of rickets and osteomalacia. In Southern Europe the main  
320 source of vitamin D was solar ultraviolet radiation B (UVB), which is able to  
321 synthesize vitamin D<sub>3</sub> in the skin through cutaneous absorption. The inhabitants  
322 of Southern Europe were therefore less dependent on diet, and the selective  
323 pressure would have been lower.

324 In Africa, the selection factor favouring the population with the mutation for  
325 persistence in the production of lactase would have been the high water content  
326 of milk, an important aspect in the arid regions of the African continent. Other  
327 authors add that the high riboflavin content in milk could act as protection  
328 against malaria caused by *Plasmodium falciparum*, an endemic disease in a  
329 large part of the African continent.

330 These circumstances would not be present in cultures without a relationship  
331 with cattle milk production, such as Amerindian or southeast Asian populations,  
332 which explains their high prevalence of lactose intolerance.<sup>38</sup>

### 333 Secondary lactase deficiency

334 In this case the affected individuals have normal enzymatic activity. A decrease  
335 in lactase occurs for various reasons and through different mechanisms, namely  
336 chronic enteropathy (secondary to immunological processes) such as coeliac  
337 disease and Chron's disease, atrophy of the villi due to caloric-protein  
338 malnutrition, and other gastrointestinal diseases that damage the brush border  
339 in the small intestine (such as infections). It is usually reversible when the  
340 underlying disease is resolved. The evolution depends on the severity and

341 duration of the damage caused to the mucosa. It is accompanied by a reduction  
342 in the activity of all disaccharidases, although lactase is the most affected.<sup>39</sup>

### 343 **3.1. - Clinical manifestations**

344 People with lactose intolerance experience typical symptoms that include  
345 abdominal pain, swelling, flatulence, diarrhoea, vomiting and bowel (or  
346 abdominal) noises, and in some cases also constipation, anorexia and weight  
347 loss. Auricchio *et al* was the first that described these symptoms in an article  
348 published in 1963.<sup>12</sup>

349 The gases produced by bacterial fermentation are responsible for the increase  
350 in intraluminal pressure and bowel transit time. Flatulence and swelling occur  
351 when gas production commences after undigested lactose comes into contact  
352 with and is digested by colonic bacteria. Studies show little or no difference in  
353 gas production between lactose malabsorbers with and without symptoms.  
354 Instead it is the sensitivity to distension that determines the likelihood of  
355 symptoms.<sup>40</sup>

356 Diarrhoea occurs as a result of acidification of the colon due to the production of  
357 short-chain fatty acids, which increase the osmotic load that involves the  
358 secretion of electrolytes and fluids and rapid transit. The stools are often  
359 voluminous, aqueous and foamy.<sup>41</sup>

360 Symptoms usually begin around one hour after the intake of lactose when its  
361 content exceeds the hydrolytic capacity of the lactase. Symptoms cease shortly  
362 after the expulsion of flatus and liquid stools. The wide variability in the severity  
363 of the symptoms that can be observed in both the same and different individuals  
364 depends on the amount and frequency of lactose ingested and the capacity to

365 digest it. This is due to the wide variability in the ability of the intestinal bacteria  
366 to ferment lactose. The symptoms get worse as more milk is consumed.<sup>42</sup>

367 On many other occasions the colon reabsorbs part of these products and does  
368 not produce symptoms, leading to an asymptomatic process. There is no  
369 consensus on the minimum dose of lactose leading to symptoms of intolerance.

370 The ingestion of 50 g of lactose produces symptoms in 80-100% of patients with  
371 hypolactasia, although those considered extremely intolerant may present  
372 symptoms with only 3 g of lactose (equivalent to about 60-70 mL of cow milk).

373 The majority of patients with this intolerance can tolerate 10-12 g of lactose  
374 (equivalent to 200-250 mL of milk) without significant symptoms.<sup>43</sup>

375 Other factors that influence the variability of manifestations include the fat  
376 content of foods with lactose, gastric emptying (which slows with higher lipid  
377 content), bowel transit time, water absorption capacity, and patients' subjective  
378 sensitivity to pain. Various studies have reported that some patients do not  
379 relate the symptoms to the intake of dairy products, and so remain undiagnosed  
380 and untreated.

381 Some authors describe non-intestinal symptoms such as headache, memory  
382 deterioration, musculoskeletal pain, heart rhythm disorders, dryness in the  
383 mucous membranes, depression, ulcers in the oral mucosa and other allergic  
384 reactions in 20-80% of patients. The cause could be the toxic effects of  
385 compounds such as acetaldehyde, acetone, ethanol, peptides and others that  
386 alter cell signals. In this case it is important to assess whether this is due to  
387 intolerance or to other disorders; up to 20% of patients with lactose intolerance  
388 may also show an allergy to milk proteins.<sup>16</sup>

389 Sometimes, food intolerance is associated to anxiety, stress, since patients may  
390 be hypervigilants to dietary factors that cause them discomfort; there are some  
391 studies about psychosocial effects of lactose intolerance in Asian and European  
392 patients showing different results. Furthermore, many self-reported lactose  
393 intolerants may suffer a “nocebo effect”, probably due to the influence of  
394 environmental factors, or the coincidence of other digestive disorders with  
395 similar symptoms.<sup>44</sup>

396

### 397 **3.2. - Diagnosis**

398 With proper diagnosis the degree of lactose intolerance can be assessed, and  
399 treatment can be prescribed.

400 The clinical history and physical examination of patients suspected of lactose  
401 intolerance are also important. The presence of symptoms such as abdominal  
402 pain, diarrhoea, nausea, flatulence and bloating are signs of intolerance to  
403 carbohydrates even though they have a nonspecific character. Other factors to  
404 be taken into account include the personal and family history, the relationship  
405 between the symptoms and the ingestion of this carbohydrate, the time elapsed  
406 between ingestion and the appearance of symptoms, the matrix in which  
407 lactose has been ingested (milk, fermented dairy products...), whether there are  
408 any conditions that speed up or slow down intestinal transit, and the age of  
409 onset. Abdominal distension and the presence of bowel noises are significant in  
410 the physical exploration, as well as perianal erythema caused by acid and  
411 explosive stools.

412 The selection of the diagnostic method will depend on the characteristics of the  
413 patient, the therapeutic objective and the available resources. These methods

414 can be classified into invasive or non-invasive and direct or indirect depending  
415 on whether they involve intestinal biopsy or not.<sup>6,30</sup>

### 416 **3.2.1. - Non-invasive or indirect methods**

417 Non-invasive or indirect methods do not involve intestinal biopsy.

#### 418 **- Suppression and provocation test with milk**

419 Lactose is excluded from the diet for two weeks, then reintroduced. If the  
420 symptomatology disappears and reappears once it is reintroduced at the end of  
421 that period (challenge test), it suggests the person is intolerant. The  
422 disadvantage is that it does not allow the diagnosis of asymptomatic individuals  
423 suffering from malabsorption.<sup>45</sup>

424 The study by Castiglione and collaborators in 2008 suggests that evaluating  
425 different variables in the anamnesis with a simple annotation system is almost  
426 as effective an evaluation method as the hydrogen test, and reduces costs and  
427 diagnosis times.<sup>46</sup>

#### 428 **- Hydrogen breath test**

429 This is the most common test, since it is a simple, practical and rapid method of  
430 determining lactose intolerance. It has a specificity of between 89% and 100%  
431 and sensitivity of between 69% and 100%. It is indicated for patients who do not  
432 have a conclusive clinical response after the suppression-provocation test. It is  
433 the test of choice in clinical practice thanks to its simplicity and safety.<sup>30</sup>

434 The test is based on the fact that intestinal bacteria degrade non-absorbed  
435 lactose and produce methane, CO<sub>2</sub> and H<sub>2</sub>. This last is disseminated through  
436 the intestinal wall and passes into the blood. It reaches the pulmonary alveoli,  
437 and is expelled in the breath. Hydrogen can be detected and quantified by gas  
438 chromatography.

439 The test consists of administering lactose (10, 20 and 40 g dissolved in 250 ml  
440 of water). Once the intake occurs, hydrogen, methane and carbon dioxide are  
441 quantified at time 0, and every 25-30 minutes during 3 hours, and the values  
442 obtained are compared. An increase of over 20 ppm in H<sub>2</sub> is considered  
443 positive; 10-20 ppm is considered an inconclusive value.<sup>47</sup> These reference  
444 values may be modified depending on the CO<sub>2</sub> and methane values measured.  
445 Ingested lactose can be marked with <sup>13</sup>C to improve sensitivity. This process is  
446 currently limited to research and is not considered appropriate for clinical use.  
447 False negative results can occur if patients have taken antibiotics for at least  
448 one month before the test, or if they have consumed laxatives, probiotics,  
449 prokinetics or electrolyte solutions for the preparation of colonoscopies, and due  
450 to hyperventilation (crying) or physical exercise. False positives can appear with  
451 the intake of non-absorbable carbohydrates the previous day, tobacco (before  
452 and during the test), hypoventilation (sleep) or bacterial overgrowth.<sup>48</sup>

#### 453 - **LacTEST**

454 Oral 4-galactosil xylose is administered. The amount of xylose is determined in  
455 an accumulated 24-hour urine sample. This test can only be applied to the adult  
456 population. The LacTEST has proved to be very cost-effective, with a higher  
457 sensitivity and specificity than the H<sub>2</sub> test and the intestinal biopsy, and a lower  
458 economic cost.<sup>49</sup>

#### 459 - **Stool acidity test**

460 The measurement of the pH of stools and reducing substances is only useful if  
461 the individual is taking lactose. It is nonspecific and has low sensitivity. In  
462 intolerant people, stools are acidic after the intake of the disaccharide. This  
463 reduction in pH is due to the presence of volatile fatty acids as a result of the

464 bacterial digestion of non-absorbed carbohydrates. If the pH is below 5.5, then it  
465 is a highly suggestive indicator of lactose malabsorption. It should be noted that  
466 the normal faecal pH of infants who are fed breast milk is lower than in the rest  
467 of the population due to the relative inadequacy of the enzyme in relation to the  
468 high amount of lactose present in breast milk, so this test loses diagnostic value  
469 in this group of individuals.

470 In addition to this method, reducing substances can be searched in faeces to  
471 detect the presence of sugars such as lactose in the stool. This test is less  
472 sensitive than the previous one because the intestinal bacteria can completely  
473 digest non-absorbed carbohydrates.<sup>50</sup>

#### 474 - Lactose tolerance test

475 Glucose is determined in the blood plasma before and after ingesting 50 grams  
476 of lactose at different time intervals. It is monitored at 0, 60 and 120 minutes.  
477 Glucose levels of over 20 mg/dL indicate lactose tolerance. False positives can  
478 occur in up to 30% of patients due to a rapid insulin response. False negative  
479 results can occur in diabetic patients or with bacterial overgrowth. Because of  
480 its low sensitivity and specificity, it should be done only if the exhaled air test is  
481 not possible.

482 Ethanol can be given orally before the ingestion of lactose to inhibit the  
483 metabolism of galactose, quantify the levels of glucose and galactose (at least  
484 20 mg/dL and 10 mg/dL respectively) and check for lactose intolerance. It has a  
485 specificity of 77-96% and a sensitivity of 76-94%, but is not sensitive to the  
486 definitive study of this intolerance.

487 It is used mainly with adult patients, and only exceptionally in children, given the  
488 fact that it has a low sensitivity and requires blood extractions every 30 minutes

489 over two hours. Although it is a simple and inexpensive test, it tends to produce  
490 confusing results and is uncomfortable for the patient, so the exhaled air test is  
491 preferred today.<sup>16,30</sup>

### 492 **3.2.2. - Invasive or direct methods**

493 Invasive or direct methods are based on biopsies of the small intestine.

#### 494 - **Study of enzymatic activity**

495 A biopsy must be done on the mucosa of the jejunum, followed by an enzymatic  
496 study. It is considered positive when the activity of the lactase is less than 10  
497 U/g with a normal intestinal mucosa. This test can give false negative results  
498 because lactase has a very irregular distribution and does not necessarily  
499 represent what happens in the entire intestine. Because of its low sensitivity, if  
500 compared with other tests such as expired hydrogen, a biopsy procedure and a  
501 specialized laboratory test are not required in the diagnosis of hypolactasia.<sup>30</sup>

#### 502 - **Rapid duodenal biopsy test (Lactose Intolerance Quick Test)**

503 This is based on a colorimetric reaction in a sample of tissue removed from the  
504 duodenum and incubated in lactose for 20 minutes. In people with normal  
505 enzyme activity the sample will change colour. The reaction was carried out into  
506 two steps: a 15-minutes lactase reaction, followed immediately by a 5-minutes  
507 signal reaction in which liberated glucose is measured by glucose  
508 oxidase/peroxidase reaction. In patients with severe duodenal hypolactasia,  
509 there is a sensitivity of 95% and a specificity of 100%. There are studies  
510 showing a high correlation between this test and the genetic study.<sup>30</sup>

### 511 **3.2.3. - Other methods**

#### 512 - **Genotypical study**

513 The genetic test can be useful for differentiating primary from secondary  
514 hypolactasia and for diagnosing the predisposition of the patients (who are not  
515 necessarily ill) to develop the primary intolerance. This is useful in subjects  
516 aged over eight years who present clinical signs and have a negative hydrogen  
517 test.

518 It identifies the different polymorphisms of the MCM6 gene and marks these  
519 phenotypes as intolerant. The genetic study can be done using the specific  
520 amplification of DNA extracted from a saliva sample, where the polymorphism  
521 of propensity to lactose intolerance by PCR in real time is located and marked  
522 with fluorescent probes. The analysis with PCR is a test with a specificity of  
523 100% and a sensitivity of 93%. This type of test allows for a quick, definitive and  
524 non-invasive diagnosis.

525 The disadvantages of the genetic method are the need for specialized  
526 laboratories and its high cost, and it is therefore not widespread.<sup>51</sup>

### 527 **3.3.- Treatment**

528 The main strategy for treating lactose intolerance is to eliminate or at least  
529 reduce the intensity of the symptoms in people with this type of intolerance,  
530 while ensuring an adequate intake of nutrients.<sup>30,52</sup>

531 The treatment will depend on the severity of the intolerance and the age of the  
532 patient. In children aged under five, this intolerance is almost always secondary  
533 and only a few require a low-lactose diet due to the high renewal of the  
534 intestinal epithelium. In the case of persistent diarrhoea, it is recommended to  
535 mix cereals with milk or to ingest fermented milk.<sup>53</sup>

536 There are four general principles for treating lactose intolerance: reducing or  
537 eliminating the intake of lactose; replacing lactose with alternative nutrients;

538 administering enzymatic substitutes or lactase supplements; and maintaining  
539 the intake of calcium and vitamin D.<sup>30</sup>

540 The other important point of treatment is patient education. The person must  
541 learn how to balance and modify their diet until the discomfort disappears. One  
542 very important aspect is how to interpret food labels correctly in order to avoid  
543 the accidental ingestion of lactose. Not only dairy products must be considered,  
544 since lactose is also used in other types of foodstuffs and in medicines.<sup>54</sup>

545 The best way to reduce lactose in the diet and meet the need for products such  
546 as calcium is to use lactose-free milk products. Calcium deficiency can produce  
547 osteoporosis, so it is important to maintain an appropriate intake of this element.  
548 There are studies showing that hypolactasia and maldigestion of lactose do not  
549 alter the absorption of calcium.<sup>55,56</sup> In contrast, other studies argue that calcium  
550 absorption is significantly reduced in intolerant individuals when they eliminate  
551 lactose from their diet, since the disaccharide stimulates its absorption in the  
552 intestine.<sup>55,56</sup>

553 In recent years the food industry has developed a wide range of high-quality,  
554 low-lactose and even lactose-free products to replace normal milk, while  
555 preserving the rest of the nutrients in the food. The aim is for an intolerant  
556 person not to have to give up consuming dairy products. Plant-based drinks  
557 (soybean, oat, rice, almonds...) are also available and are marketed as milk  
558 substitutes with added sugars and other substances, together with vitamin D  
559 and calcium to enrich their nutritional value.<sup>57</sup>

560 People who do not consume milk and milk products need dietary alternatives for  
561 certain nutrients such as calcium and vitamin D. Other sources of calcium, apart  
562 from dairy products, include legumes (beans, chickpeas etc.) or vegetables

563 such as cabbage. Spinach and chard can be excluded since they contain  
564 oxalates and block the absorption of the ion. Animal-based foods are also  
565 important, including fish (sardines, salmon etc.) and shellfish (prawns, shrimps,  
566 clams etc.). Vitamin D can be obtained from oily fish like salmon, from eggs,  
567 liver and other foods, and mainly from exposure to sun.

568 Seventy to eighty percent of patients have a positive response to a lactose-free  
569 diet. In other cases, the persistence of symptoms may be caused by another  
570 underlying cause such as irritable bowel syndrome.<sup>54</sup>

571 As previously mentioned, the vast majority of intolerant individuals can tolerate  
572 up to 100-200 ml of milk, which corresponds to about 5-10 g of lactose,  
573 distributed throughout the day. It is worth noting that whole milk is better  
574 tolerated than skimmed or semi-skimmed dairy products, as fats can delay  
575 gastric emptying. The intake of dairy products and other foods such as biscuits,  
576 bread, etc. also improves tolerance. Butter can contain traces of lactose, and  
577 the disaccharide content can be increased if milk solids are added to the  
578 product.<sup>58</sup>

579 After an initial period of lactose exclusion (at least four weeks), it is sometimes  
580 recommended to introduce small quantities in the diet to check the tolerance  
581 and the adaptation of the colonic flora. Dietary control depends on the affected  
582 population learning by trial and error how much lactose they can tolerate.<sup>59</sup>

583 For secondary lactase deficiency the most important strategy is to eliminate the  
584 origin of the pathology. The lactase activity will gradually recover in weeks or  
585 months once the damage is removed from the intestinal mucosa.

#### 586 **4. - FOOD PRODUCTS FOR LACTOSE INTOLERANT INDIVIDUALS**

##### 587 **4.1. - Delactosation methods**

588 Delactosation is a technological process that consists of eliminating lactose  
589 from milk, or reducing its concentration below a certain threshold. Regulation  
590 (EU) No 1169/2011 sets out rules for labelling substances with a scientifically  
591 proven allergenic or intolerant effect. These indications are important to enable  
592 lactose-intolerant individuals to make safe choices. However, as recognized in  
593 Regulation (EU) No 609/2013, labelling rules for reference levels to indicate the  
594 absence or reduced presence of lactose in food are currently not harmonized in  
595 the European Union, and must be included in Regulation (EU) 1169/2011.  
596 These rules should take into account the scientific opinion of authorities on  
597 lactose thresholds for lactose intolerance and galactosaemia, which  
598 recommends that until rules can be established for claims concerning the  
599 absence or reduced presence of lactose in food, a maximum level of 0.01% for  
600 lactose-free products and 1% for low-lactose products could be adopted as  
601 suitable thresholds for lactose-intolerant individuals. Products in which the  
602 lactose is enzymatically hydrolyzed to glucose and galactose and from which  
603 the galactose has not been removed are not suitable for patients with  
604 galactosaemia, regardless of the residual lactose content, and require different  
605 thresholds.<sup>60,61,62</sup>

606 To achieve these levels, lactose can be removed from dairy products in two  
607 ways:

608 The first consists of hydrolyzing the lactose in milk by means of the  $\beta$ -  
609 galactosidase enzyme which converts lactose into glucose and galactose. This  
610 is done by adding the enzyme to milk in storage tanks. The process is  
611 conditioned by the lactose concentration in the milk, the dose of the enzyme,  
612 the temperature of the milk and the time of the process.<sup>16</sup>

613 The enzyme is obtained from different strains of microorganisms such as the  
614 yeasts *Kluyveromyces lactis*, *Aspergillus oryzae* and *A. niger*. The first is used  
615 primarily for the delactosation of milk while the others are often used to obtain  
616 lactose-free cheese whey. Different methods are used to solubilize the  $\beta$ -  
617 galactosidase depending on its location within the cell and its stability.  
618 Mechanical methods are preferred to autolytic methods, although the former are  
619 more expensive and involve separating the enzyme from the cell remains.  
620 However autolysis requires a temperature range that could alter the enzyme,  
621 and the removal of the detergents used.<sup>63</sup>

622 The delactosation process takes place at a temperature of 6-10° C for 15 to 20  
623 hours. This temperature is below the optimum efficiency temperature, which is  
624 35-40° C, and the process therefore takes longer. This temperature control is  
625 important for preventing the growth of psychrophilic and psychotropic residual  
626 bacterial flora which, although the milk undergoes heat pretreatment, can affect  
627 the process through the action of thermo-resistant enzymes (lipases and  
628 proteases). This method is the most highly rated by the industry despite its  
629 disadvantages, such as the time required and the high cost of producing the  
630 enzymes. The effectiveness of the process will depend on the rate of hydrolysis  
631 of the lactose. In the conditions described above, this percentage is about 85%.  
632 Delactosed milks produced using this method have a more intense cooked  
633 flavour and sweetness, since glucose and galactose have a greater sweetening  
634 power than lactose, which may sometimes pose an obstacle for its  
635 consumption.<sup>64</sup>

636 The second method consists of a variation of the former, with the prior  
637 ultrafiltration of milk followed by the action of the lactase enzyme to reduce the

638 lactose to the desired levels. This method eliminates salts, which must be  
639 compensated after delactosation. It also involves more manipulation of the  
640 product than the previous methods, so the dairy products obtained in this case  
641 are known as lacteal products.<sup>16</sup>

#### 642 **4.2. - Lactase food supplements**

643 When lactose cannot be avoided or when a person with symptoms decides to  
644 consume foods that contain the disaccharide, lactase supplements can be  
645 used. They are administered in capsules, chewable tablets or in liquid  
646 preparations. One option is to add commercial lactase to milk followed by  
647 incubation for several hours (it is advisable to do this approximately 10 hours  
648 before consumption as this has revealed greater tolerance).<sup>65</sup>

649 The characteristics and properties of these preparations vary depending on the  
650 source of the enzyme. Those of fungal origin have a higher thermal stability,  
651 with the maximum range of activity varying between 35 and 55° C, and the  
652 optimal pH between 4.5 and 6.5. The enzymes obtained from bacteria and  
653 yeasts have an optimal activity at 37° C and close to neutral pH. Their activity  
654 decreases at a temperature of 55° C and a pH of 5.3, and ceases totally at pH  
655 4.5.<sup>66</sup>

656 Other preparations include lactase, which is directly ingested and has enough  
657 stability to overcome heartburn (inside coated oral dosage forms). These  
658 preparations are unable to hydrolyze all dietary lactose, and the results vary  
659 depending on each patient so the dosage must be set individually. Intolerant  
660 patients can use these supplements to continue to consume dairy products,  
661 which are the main sources of calcium, vitamin D, riboflavin, and proteins. They

662 are less commercially successful than lactose-free or low-lactose milk and dairy  
663 products.<sup>67</sup>

664 The preparations on the market contain lactase produced by the yeast  
665 *Kluyveromyces lactis* or *Aspergillus oryzae*. They are odourless, tasteless liquid  
666 products that can be added to milk and dairy products such as creams and  
667 chocolate, and transform 70-90% of lactose into glucose and galactose. They  
668 can also be found in tablets and chewable tablets for immediate consumption  
669 before a meal containing food with lactose. It may be necessary to repeat the  
670 administration if the individual continues to consume dairy products.

671 Microencapsulation of lactase (with agarose and a coating of chocolate) is a  
672 technological process that has been introduced as an option to meet the  
673 growing demand for alternatives for people who are intolerant to lactose.

674 Microencapsulation is a technology used by the food and pharmaceutical  
675 industry for encapsulating solid, liquid or gaseous materials. The advantage is  
676 that it releases active ingredients at controlled speeds under specific conditions,  
677 and can also protect them from reactions with other compounds present in food,  
678 and prevent oxidation. Microcapsules help fragile materials withstand  
679 processing and packaging and improve the flavour, aroma, stability, nutritional  
680 value and appearance of the products. In recent years the microencapsulation  
681 of lactase has proven to be a technologically viable alternative for lactose  
682 intolerant patients.<sup>68</sup>

### 683 **4.3. - Probiotics**

684 The term probiotic was first proposed by Lilly and Stillwell to describe  
685 substances produced by a microorganism that stimulates the growth of another  
686 microorganism.<sup>69</sup> Nowadays, probiotics are defined by the WHO as "live

687 microorganisms that, when administered in adequate amounts, confer a health  
688 benefit on the host".<sup>70</sup>

689 Within the framework of the production of functional foods, the use of  
690 microorganisms can be very useful in the dietary treatment of various  
691 pathologies and disorders such as lactose intolerance, to reduce various types  
692 of diarrhoea, and they also have an immunopromotory and preventive effect on  
693 the development of colon cancer.<sup>71</sup> The most frequent starter cultures belong to  
694 the lactic acid bacteria group.

695 Yogurt is obtained from the fermentation of *Streptococcus thermophilus* and  
696 various species of *Lactobacillus*, usually *L. bulgaricus*. Intestinal bacteria  
697 *Bifidobacterium* is included in some of their starter cultures. Yogurt contains  
698 significant amounts of calcium that is bioavailable because it is present in ionic  
699 form. The acidity of the yogurt facilitates its intestinal absorption.<sup>72</sup> The  
700 fermentation of some other products such as kefir also involves yeast, creating  
701 intense interdependent relationships between the organisms considered as  
702 probiotic.

703 Various properties related to the improvement and maintenance of health have  
704 been attributed to fermented milks since their origins, probably in the Middle  
705 East or the Balkans.<sup>73</sup> In the particular case of lactose intolerance, several  
706 studies show that the continuous consumption of yogurt for six months  
707 improves the digestion and absorption of lactose, although the fermentation  
708 process usually reduces the amount of disaccharide by 20%.

709 The increase in lactose absorption appears to be at least partially due to the  
710 microbial  $\beta$ -galactosidase, which is still active when it reaches the intestine. This  
711 may be caused by the excellent buffer capacity of the yogurt during gastric

712 transit (favoured by casein micelles, calcium phosphate and lactic acid)<sup>74</sup>, and  
713 the protection of the enzyme by the microbial wall and membrane. It depends  
714 on the individual capacity of acid secretion and gastric emptying time, the  
715 amount of yogurt ingested and the interaction with other foods ingested at the  
716 same time.<sup>75</sup> Other factors include the actions of the secretions and enzymes  
717 from the pancreas and intestine, the longer bowel transit time of the yogurt and  
718 the lipid emulsion formed by the bile salts. The function of bile acids in this  
719 regard is not known for certain, since yogurt bacteria are not resistant to these  
720 salts. This could be due to the increased permeability of the bacterial cells,  
721 which allows the hydrolysis of the disaccharide in the cells; or because they  
722 enable the release of the enzyme from the intracellular space to the lumen.<sup>76</sup>  
723 Some literature reviews conclude that certain strains of probiotics can have  
724 beneficial effects on lactose intolerance<sup>77</sup>, while other reviews contradict this by  
725 stating that they are only useful in the treatment of flatulence in adult  
726 hypolactasia.<sup>78</sup> More research is therefore necessary in clinical studies that  
727 include specific strains and objective methodologies.<sup>79</sup>

#### 728 **4. CONCLUSIONS**

729 Scientific knowledge of lactose intolerance has advanced significantly in recent  
730 decades, especially in terms of the genetic basis and diagnosis of this condition.  
731 Although the exact mechanism involved in the decline of lactase activity at the  
732 end of breastfeeding is still unclear, it has been suggested that it may include a  
733 drop in mRNA production, an alteration in genetic transcription or translation  
734 and even a decline in the number of enterocytes that produce lactase. However,  
735 some enzymatic activity may persist after weaning; the cultural-historical  
736 hypothesis postulates that the mutation that gives rise to lactase persistence in

737 adulthood appeared about 10,000 years ago in the inhabitants of Northern  
738 Europe. Gene polymorphisms linked to this condition have been sequenced for  
739 different human races.

740 As about 70% of the whole world population evolves to reduce lactase activity  
741 during their life, the industry has developed many products as alternatives to  
742 milk products. Many intolerant individuals can tolerate about 5-10 g of lactose  
743 distributed throughout the day. Probiotics have been proposed as an alternative  
744 that could avoid some symptoms of lactose intolerance thanks to the microbial  
745  $\beta$ -galactosidase, although the results are still contradictory and further research  
746 is needed. Many products are also marketed today as alternatives to dairy  
747 products for lactose intolerants, such as plant-based drinks and lactose-free  
748 dairy products obtained from the enzymatic hydrolysis of lactose using lactase  
749 from different strains of microorganisms such as the yeast *Kluyveromyces*  
750 *lactis*. A recommendation by the EFSA for labelling these products specifies a  
751 maximum level of 0.01% for lactose-free products, and 1% for low-lactose  
752 products. As these indications are important for lactose-intolerant people,  
753 labelling rules for low-lactose foods need harmonization in the European Union  
754 to enable lactose-intolerant people to make safe choices.

755

#### 756 ACKNOWLEDGEMENTS

757 This study was supported by the ALIMNOVA (951505) UCM research group.

758

#### 759 REFERENCES

- 760 1 M. C. Latham. Nutrición humana en el mundo desarrollado. Colección FAO:  
761 Alimentación y nutrición N° 29. De las Naciones Unidas para la Agricultura y  
762 Alimentación. Roma, 2002. pp. 1-25.
- 763 2 E. Guerra Hernández. Azúcares, miel y productos de confitería. *Tratado de*  
764 *Nutrición. Tomo II. Composición y calidad nutritiva de los alimentos.* (2ª ed) In:  
765 Gil, A. (Ed) *Tratado de Nutrición. Tomo II. Composición y calidad nutritiva de*  
766 *los alimentos..* Sociedad Española de Nutrición Parenteral y Enteral. Madrid:  
767 Editorial Médica Panamericana, 2010, pp. 221-248.
- 768 3 F. Casellas, A. Aparici, M. Casaus, P. Rodríguez and J. Malagelada. Impact  
769 of orocecal transit time patient's perception of lactose intolerance. *Rev. Esp.*  
770 *Enf. Dig.*, 2013, 105 (1) 13-18.
- 771 4 M. D. Marrodán Serrano. Adaptación genética de las poblaciones e  
772 intolerancias de los alimentos: lactosa, gluten, alcohol. *Revista de Nutrición*  
773 *Práctica.*, 2011, 15, 91-92.
- 774 5 R. Romero del Castillo Shelly, J. Mestres Lagarriga. *Productos lácteos.*  
775 *Tecnología.* Barcelona: Ediciones Universidad Politécnica de Catalunya, 2004,  
776 pp. 21-33.
- 777 6 F. Allende. Intolerancia a la lactosa y otros disacáridos. *Gastr. Latino Am.*,  
778 2007, 18 ( 2), 152-155.
- 779 7 M. Calvo Rebollar. La ciencia y la tecnología de los alimentos. Algunas notas  
780 sobre su desarrollo histórico. *Alimentaria.*, 2004, 4, 19-34.
- 781 8 A. Varnam, J. Sutherland. *Milk and milk products. Technology, chemistry and*  
782 *microbiology.* Wallington, Survey: Chapman&Hall. 1994, pp. 22-23.
- 783 9 T. Palmer and P. Bonner. *Enzymes: Biochemistry, Biotechnology, Clinical*  
784 *Chemistry.* Second edition. Cambridge UK: Horwood Publishing Limited, 2007,  
785 pp. 81-82.

- 786 10 R. G. Jensen. *Handbook of milk composition* San Diego. USA: Academic  
787 press. 1995, p3.
- 788 11 WHO. 1999. Report of the twenty-third session of the joint FAO/WHO Codex  
789 Alimentarius Commission. Rome, 28 June - 3 July 1999. Geneva, Switzerland:  
790 World Health Organization.
- 791 12 M. C. Lomer, G. C. Parkes and J. C. Sanderson. Lactose intolerance in  
792 clinical practice-myths and realities. *Aliment. Pharmacol. Ther.* , 2008, (27),94-  
793 96.
- 794 13 M. Amiri, L. Diekmann, M. von Köckritz-Blickwede and H. Y. Naim. The  
795 diverse forms of lactose intolerance and the putative linkage to several cancers.  
796 *Nutrients*, 2015, 7(9), 7209-7230.
- 797 14 P. García Luna and G. López Gallardo. Evaluación de la absorción y  
798 metabolismo intestinal. *Nutr. Hosp.*, 2007, 5-13.
- 799 15 I. Labayen and J. A. Martínez. Prebióticos y probióticos: Mecanismos de  
800 acción y sus aplicaciones clínicas. *Gastroenterol. Hepatol.*, 2003, 26 (Supl 1),  
801 64.
- 802 16 P. Gil Gregorio. Intolerancia a la lactosa. Una patología emergente.  
803 *Sociedad Española de Geriatria y Gerontología*, 2013, 8-16.
- 804 17 L. Zecca, J. E. Mesoneroa, A. Stuzt, J. C. Poireec, J. Giudicellic, R. Cursoid,  
805 S. M. Gloora and G. Semenzab. Intestinal lactase-phlorizin hydrolase (LPH):  
806 the two catalytic sites; the role of the pancreas in pro-LPH maturation. *FEBS*  
807 *Lett.*, 1998, 225-228.
- 808 18 Y. Wang, C. B. Harvey, E. J. Hollox, A. D. Phillips, M. Poulter, P. Clay, J. A.  
809 Walker-Smith and D. M. Swallow. The genetically programmed down-regulation  
810 of lactase in children. *Gastroenterology*, 1998, 1230-1236.

- 811 19 T. H. Arola. Diagnosis of hypolactasia and lactose malabsorption. *Scand. J.*  
812 *Gastroenterol.* 1994. (Suppl): 29, 26-35.
- 813 20 R. Magiera, C. C. Schürer-Maly, A. Morttsiefe, H. H. Abhoiz, F. E. Mly and  
814 M. Pentzek. Are there differences between patients with and without the  
815 homozugous--13910CC genetic variant in the MCM6 gene upstream from the  
816 lactase gene?- A non randomised, two armed intervention study without control  
817 group. *Clin Lab.*, 2010, 60(10): 1617-25.
- 818 21 J. L. Rosado. Intolerancia a la lactosa. *Gac. Med. Mex.*, 2016, 152 Suppl 1,  
819 67-73.
- 820 22 L. Jiménez Montoya and J. Martínez Sarabia. Lactase non-persistent:  
821 Causes, effects, diagnosis and treatment. *Revista Complutense de Ciencias*  
822 *Veterinarias*, 2017, 11(especial), 72-77.
- 823 23 E. Kelly. *Encyclopedia of human genetics and diseases*. Wetsport  
824 Connecticut, USA: Greenwood Publishing Group. 2013, pp 462-463.
- 825 24 H. Y. Hassan, A. van Er, M. Jaeger, H. Tahir, M. Oosting, L. Joosten and M.  
826 G. Netea. Genetic diversity of lactase persistence in East African populations.  
827 *BMC Research*, 2016, *Notes*: 9, 8.
- 828 25 L. McBean and G. Miller. Alaying fears and fallacies about lactose  
829 intolerance. *J. Am. Diet. Assoc.*, 1998, 98 (6),671-676.
- 830 26 V. Labrie, O. J. Buske, E. Oh, R. Jeremian, C. Ptak, G. Gasiūnas, R.  
831 Petereit, A. Žvirblinė, K. Adamonis, E. Krikiene, K. Koncevičius, J. Gordevičius,  
832 A. Nair, A. Zhang, S. Ebrahimi, G. Oh, V. Šikšnys, L. Kupčinskas, M. Brudno  
833 and A. Petronis. Lactase non-persistence is directed by DNA variation-  
834 dependent epigenetic aging. *Nat. Struct. Mol. Biol.*, 2016, 23(6), 556-573.

- 835 27 D. M. Swallow Genetics of lactose intolerance. *Annu. Rev. Genet.*, 2003,  
836 37, 197-219.
- 837 28 A. Gil Hernández, C. Aguilera García and C. Gómez Llorente. *Tratado de*  
838 *Nutrición. Tomo I. Bases Fisiopatológicas y Bioquímicas de la Nutrición.*  
839 *Nutrigenómica.* (2ª ed). In: Sánchez de Medina, F. (Ed.) Sociedad Española de  
840 Nutrición Parenteral y Enteral, Madrid: Editorial Médica Panamericana, 2010,  
841 pp. 749-806.
- 842 29 A. Doval Fernández. Reacciones de hipersensibilidad a los alimentos.  
843 Normativa en la aplicación en el control oficial de alérgenos presentes en los  
844 alimentos. *Documentos técnicos de Higiene y Seguridad Alimentarias 1.*  
845 *Consejería Sanidad C. Madrid*, 2015, 7.
- 846 30 E. Adrada Trujillo, R. Albañil Ballesteros, B. Juanes de Toledo, A. Pando  
847 Bravo. Intolerancia a los hidratos de carbono: Lactosa y Fructosa. *Guías de*  
848 *actuación conjunta Pediatría Primaria-Especializada*, Grupo de  
849 Gastroenterología Pediátrica Zona Sur-Oeste Madrid, 2014, 1-15.
- 850 31 K. Kaur, S. Mahmood, A. Mahmood. Hypo-lactasia as a molecular basis of  
851 lactose intolerance. *Indian J. Biochem. Biophys.*, 2006, 43(5), 267-274.
- 852 32 Y. Deng, B. Misselwitz, N. Dai and M. Fox. Lactose intolerance in adults:  
853 Biological mechanism and dietary management. *Nutrients*, 2015, 7, 8020-8035.
- 854 33 M. Koukkanen, J. Kokkonen, N. S. Enattah, T. Ylisaukko-oja, H. Komu, T.  
855 Varilo and L. Peltonen. Mutations in the translated Region of the lactase gene  
856 (LCT) underline congenital lactase deficiency. *AJHG*, 2006, 78 (2), 339-344.
- 857 34 M. Heyman M. Lactose Intolerance in Infants, Children and Adolescents.  
858 *Pediatrics*, 2006, 118 (3), 1279-1286.

- 859 35 T. Sahi. Hypolactasia and lactase persistence. Historical review and the  
860 terminology. *Scand. J. Gastroenterol.*, 1994, 202(Suppl), 1-20.
- 861 36 R. Leis, R. Tojo, P. Pavón, A. Dowes. Prevalence of lactose malabsorption  
862 in Galicia. *J. Pediatr. Gastroenterolo. Nutr.*, 1997, (25), 296-300.
- 863 37 R. Berni Canani, V. Pezzella, A. Amoroso, C. DiScala and A. Passariello.  
864 Diagnosing and treating intolerance to carbohydrates in children. *Nutrients*,  
865 2016, 8(3), 157.
- 866 38 A. Beja-Pereira, G. Luikar, P. Englan, D. Bradley, O. Jann, G. Bertorelle, A.  
867 Chamberlain, T. Nunes, S. Metodiev, N. Ferrand and G. Erhardt. Geneculture  
868 coevolution between cattle milk protein genes and human lactase genes. *Nat.*  
869 *Genet.*, 2003, Dec: 35(4), 311-314.
- 870 39 S. Mishkin. Dairy sensitivity, lactose malabsorption and elimination diets in  
871 inflammatory bowel disease. *Am. J. Clin. Nutr.*, 1997, 65, 564-567.
- 872 40 Y. Zhu, X. Zheng, Y. Cong, H. Chu, M. Fried, N. Dai and M. Fox. Bloating  
873 and distention in irritable bowel syndrome: the role of gas production and visceral  
874 sensation after lactose ingestion in a population with lactase deficiency. *Am.J.*  
875 *Gastroenterol*, 2013, 108(9), 1516-25.
- 876 41 T. He, M. G. Priebe, F. Harmsen Stellard, X. Sun, G. W. Welling and R. J.  
877 Vonk. Colonic fermentation may play a role in lactose intolerance in humans. *J.*  
878 *Nutr.*, 2006, 136, 58-63.
- 879 42 L. N. Auricchio and C. S. Pitchumoni. Lactose intolerance. Recognizing the  
880 link between diet and discomfort. *Postgraduate Med.*, 1994, 95 (1), 113-120.
- 881 43 Y. Deng, B. Misselwitz, N. Dai, M. Fox. Lactose intolerance in adults:  
882 Biological mechanism and dietary management. *Nutrients*, 2015, 7(9), 8020-  
883 8035.

- 884 44 X. Zheng, H. Chu, Y. Cong, Y. Deng, Y. Long, Y. Zhu, Y. Zhu, D. Polh, M.  
885 Fried, N. Dai and M. Fox. Self-reported lactose intolerance in clinic patients with  
886 functional gastrointestinal symptoms: prevalence, risk factors and impact on  
887 food choices. *Neurogastroenterology and Motility*, 2015, 27(8), 1138-1146.
- 888 45 E. La Orden Izquierdo, I. Carabaño Aguado and F. J. Pelayo García.  
889 Situación actual de la intolerancia a la lactosa en la infancia. *Rev. Pediatr.*  
890 *Aten. Primaria.*, 2011, 13 (50), 2-4.
- 891 46 F. Castiglione, E. Di Girolano, C. Ciacci, N. Caporaso, L. Pasquale, A.  
892 Cozzolino, A. Tortora, A. Testa and A. Rispo. Lactose malabsorption: Clinical or  
893 breath test diagnosis? e-SPEN, *The European e-Journal of Clinical Nutrition*  
894 *and Metabolism*, 2008, 3, 316-320.
- 895 47 J. Yang, Y. Deng, H. Chiu, Y. Cong, J. Zhao, D. Pohl, B. Misselwitz, M.  
896 Fried, N. Dai and M. Fox. Prevalence and presentation of lactose intolerance  
897 and effects on dairy products intake in healthy subjects and patients with  
898 irritable bowel syndrome. *Clinical gastroenterology and hepatology*. 2013, 11,  
899 262-268.
- 900 48 R. J. M. Brummer, M. Karibe and B. W. Stockbrügger. Lactose  
901 malabsorption. Optimization of investigational methods. *Scand. J.*  
902 *Gastroenterol.*, 1993, 28 (Suppl): 65-69.
- 903 49 J. Darbà, L. Kaskens and A. García. Estudio de impacto presupuestario y  
904 coste efectividad de la introducción de lacTEST en el diagnóstico de la  
905 hipolactasia en España. *PharmacoEco. Span. Res. Artic.*, 2014, (11), 123.
- 906 50 F. Alliende, L. Rodriguez and G. Ríos. Intolerancia a la lactosa y otros  
907 hidratos de carbono. *Contacto Científico, Pediatría del siglo XXI*. 2016 6(6),  
908 107-111.

- 909 51 N. Enattah, T. Sabi, E. Savilahti, J. D. Terwillige and L. Järvela. Identification  
910 of a variant associated with adult-type hypolactasia. *Nat. Genet.*, 2002, 30(2),  
911 233-237.
- 912 52 F. J. Suchy, P. M. Brannom, T. O. Carpenter, J. R. Fernández, V. Gilsanz, J.  
913 B. Gould, K. Hall, S. L. Hui, J. Lupton, J. Menelle, N. J. Miller, S. K. Osganian,  
914 D. E. Sellmeyer and M. A. Wolf. National Institute of Health Consensus  
915 Development Conference: Lactose intolerance and health. *Ann. Intern. Med.*,  
916 2010, Jun 15 152 (12), 792-796.
- 917 53 E. H. Rings, R. J. Grand and H. A. Buller. Lactose intolerance and lactase  
918 deficiency in children. *Curr. Op. Pediatr.*, 1994, (6), 562-567.
- 919 54 D. Rodríguez Martínez and L. F. Pérez Méndez. Intolerancia a la lactosa.  
920 *Esp. Enferm. Digest.*, 2006, 98 ( 2), 143.
- 921 55 M. Griessen, B. Couchet, F. Infante, A. Jung, P. Bartholdi, A. Donath, E.  
922 Loizeau and B. Courvoisier. Calcium absorption from milk in lactose-deficient  
923 subjects. *Am. J. Clin. Nutr.*, 1989, 49, 377.
- 924 56 N. Enattah, V. Valimaki and H. J. Valimakim. Molecularly defined lactose  
925 malabsorption, peak bone mass and bone turnover rate in young Finish men.  
926 *Calcif. Tissues Int.*, 2004. 75, 488-493.
- 927 57 O. E. Mäkinen, V. Wanhalinna, E. Zannini E and E. K. Arendt. Foods for  
928 special dietary needs: Non-dairy plant-based milk substitutes and fermented  
929 dairy-type products. *Crit. Rev. Food. Sci. Nutr.*, 2016, 56(3), 339-49.
- 930 58 L. A. Houghton, Y. F. Magnall and N. W. Read. Effect of incorporating fat  
931 into liquid test meal on the relation between intragastric distribution and gastric  
932 emptying in human volunteers. *Gut.*, 1990, 31, 1226-1229.

- 933 59 A. Zugasti Murillo. Intolerancia alimentaria. *Endocrinol Nutr.*, 2009, 56(5),  
934 541-550.
- 935 60 European Food Safety Authority. Scientific Opinion on lactose thresholds in  
936 lactose intolerance and galactosaemia EFSA Journal 2010;8(9):1777.
- 937 61 European Parliament and Council (2011) Regulation (EU) No 1169/2011 of  
938 The European Parliament and of the Council of 25 October 2011 on the  
939 provision of food information to consumers. Official Journal of the European  
940 Union, 22.11.2011: L304/18-L304/63.
- 941 62 European Parliament and Council. Regulation (EU) No 609/2013 of The  
942 European Parliament and of the Council on food intended for infants and young  
943 children, food for special medical purposes, and total diet replacement for  
944 weight control: L181/35-L181/56.
- 945 63 X. Montiel, I. Carruyo, L. Marcano and M. Marvárez. Optimización del  
946 proceso de extracción de la lactasa de *Kluyveromyces marxianus* atcc 8554,  
947 para su aplicabilidad en la industria láctea. *Revista científica FCU-LUZ*, 2005,  
948 XV (5), 476-482.
- 949 64 P. Usme, D. M. Jaramillo and F. Álvarez. Microencapsulación de la lactasa  
950 como estrategia para mejorar la estabilidad y la aplicación en la industria de los  
951 alimentos: *Corporación Universitaria Lasallista. Facultad de Ingeniería.*  
952 *especialización en alimentación y nutrición. Caldas. Antioquía*, 2013, 21-23.
- 953 65 M. Montalvo, V. Curigliano, L. Santoro, M. Vastola, G. Cammarota, R.  
954 Manna. A. Gasbarrini and G. Gasbarrin. Management and treatment of lactose  
955 malabsorption. *World J. Gastroenterol.*, 2006, (12), 187-191.
- 956 66 C. E. Sánchez Jáuregui, M. F. Rosales Medina and A. C. Bustamante  
957 Gaviláñez. Modelo de hidrólisis de lactosa para fermentación láctica en una

- 958 base probiótica y simbiótica. *Revista Tecnológica ESPOL-RTE*, 2015, 28 (3),  
959 53-68.
- 960 67 F. Suárez, D. A. Savaiano and M. Levitt. Review article: the treatment of  
961 lactose intolerance. *Aliment. Pharmacol. Ther.*, 1998, (9), 589-597.
- 962 68 A. Nussinovitch, N. Chapnik, J. Gal and O. Froy. Delivery of lactase using  
963 chocolate-coated agarose carriers. *Food Res. Int.*, 2012, (46), 41-45.
- 964 69 D. N. Lilly and R. H. Stowell. Probiotics: growth promoting factors produced  
965 by microorganisms. *Science*, 1965, 147, 747-748.
- 966 70 M. E. Sanders. Probiotics: Definition, sources, selection and uses. *Clin.*  
967 *Infect. Dis.*, 2008, 46 (Supplement 2), 58-61.
- 968 71 W. N. Nanayakkara, P. M. Skidmore, L. O'Brien, T. J. Wilkinson and R. B.  
969 Geary. Efficacy of the low FODMAP for treating irritable bowel syndrome: the  
970 evidence to date. *Clin. Exp Gastroenterolo.*, 2016, 9:131
- 971 72 O. Adolfsson, S. Nikbin, R. M. Russell. Yogurt and gut function. *Am. J. Clin*  
972 *Nutr.*, 2004, 80, 245-256.
- 973 73 C. I. Vénica, M. Perotti, I. V. Wolf, C. V. Bergamini and C. A. Zalazar.  
974 Intolerancia a la lactosa. Productos lácteos modificados. *Tecnología Láctea*  
975 *Latinoamericana*, 2011, 65, 50-55.
- 976 74 Silanikove N, Leitner G, Merin U. The Interrelationships between Lactose  
977 Intolerance and the Modern Dairy Industry: Global Perspectives in Evolutional  
978 and Historical Backgrounds. *Nutrients*. 2015 7(9), 7312-7331
- 979 75 T. H. Vesa, P. Marteau, S. Zidi, F. Briet, P. Pochart and J. C. Rambaud.  
980 Digestion and tolerance from yogurt and different semi-solid fermented dairy  
981 products containing *Lactobacillus acidophilus* and *Bifidobacteria* in lactose  
982 maldigesters- Is bacterial lactase important? *Eur. J. Nutr.*, 1996, 50, 730-733.

- 983 76 C. M. Kotz, J. K. Furne, D. A. Savaiano and M. D. Levitt. Factors affecting  
984 the ability of a high  $\beta$ -galactosidase yogurt to enhance lactose absorption. *J.*  
985 *Dairy Sci.*, 1994, 77, 3538-3544.
- 986 77 B. Sánchez, S. Delgado, A. Blanco-Míguez, A. Lourenço, M. Gueideme  
987 and A. Margolles. Probiotics, gut microbiota, and their influence on host health  
988 and disease. *Mol. Nutr. Food Res.*, 2017, 61.
- 989 78 T. J. Wilt, A. Shaukat, T. Shamliyan, C. Brent, R. MacDonald, J. Tacklind, I.  
990 Rutks, J. Schwarzenberg, R. Kane and M. Levitt. Lactose intolerance and  
991 health. *Evidence Reports/ Technology Assessment*: 192. Rockville (MD):  
992 Agency for Healthcare Research and Quality (US); 2010, Feb. Report No.: 10-  
993 E004, 17-26.
- 994 79 C. Manzano, D. Estupiñán and E. Poveda. Clinical effects of probiotics: what  
995 does the evidence says. *Rev. Chil. Nutr.*, 2012, 39 (1), 98-103.
- 996

997

998 **Table 1: Frequency distribution of lactose intolerant people among**  
 999 **various ethnic groups<sup>33</sup>.**

<b>Populations subgroups</b>	<b>Frequency of Lactose intolerance (%)</b>
Northern-Central Europe	5
Southern Europe	15-20
African-Americans	60-70
Asia (SE)	90

1000

1001 **Table 2: Genetics polymorphisms of lactase persistence / non-persistence**  
 1002 **<sup>21,22</sup>.**

	<b>Lactase persistent</b>	<b>Non lactase persistent</b>
<b>LCT-13910</b>	C/T and T/T	C/C
<b>LCT-22018</b>	G/A and A/A	G/G

1003 C: Cytosine, T: Thymine, G: Guanine, A: Adenine.

1004

1005

1006

1007


1008

1009

1010

1011

A review on the current knowledge about lactose malabsorption and intolerance is presented including biochemistry, physiology, diagnosis and dietary management.



254x190mm (72 x 72 DPI)